We may have another super VVUS up day! Just released on the wire:
Tuesday March 31, 7:27 am Eastern Time
Company Press Release
VIVUS Expands Sales Force
Primary Care Physicians As Main Target
MOUNTAIN VIEW, Calif.--(BW HealthWire)--March 31, 1998--VIVUS, Inc. (NASDAQ:VVUS - news) today announced an agreement to expand its sales organization from 74 to approximately 280 to increase the Company's coverage of the primary care physician (PCP) audience for its product MUSE(R) (alprostadil), a treatment for impotence. The Company expects that as of May 1998, these new representatives will have completed their training and will begin calling on targeted primary care physicians nationwide.
''The addition of these new sales representatives, along with our current territory managers, will allow VIVUS to increase our total physician coverage to 55,000 physicians,'' said Julian Gangolli, Vice President, Sales and Marketing of VIVUS. ''The expansion of the sales force is part of VIVUS' strategy to take advantage of the anticipated growth in demand. With the introduction by competitors of additional options for the treatment of impotence, we expect that more men will be brought into their PCP's office. Our presence in these doctors' offices will be important in ensuring that physicians and patients alike are educated about the benefits of MUSE.''
Innovex, a contract pharmaceutical organization and a division of Quintiles International, will provide VIVUS approximately 200 dedicated, full-time, primary care physician sales representatives. ''Innovex provides us with an immediate, experienced primary care physician sales force. These new representatives will be focusing solely on MUSE,'' stated Gangolli.
Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic systems for the treatment of erectile dysfunction, commonly referred to as impotence. VIVUS has pioneered a novel therapy for erectile dysfunction known as MUSE. This therapy consists of a proprietary, non-invasive drug delivery system that delivers alprostadil via the urethra. Since the introduction of the product, MUSE has established itself as the most frequently prescribed treatment for impotence by specialists. To date, over 500,000 men have used MUSE.
Note to Editors: MUSE is a registered trademark of VIVUS, Inc. Additional written materials, recent releases and company information are available through a variety of sources, including: the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719).
--------------------------------------------------------------------------------
Contact:
VIVUS, Inc.
Nina W. Ferrari, 650/934-5200 (Corporate Communications)
David Yntema, 650/934-5200 (CFO)
--------------------------------------------------------------------------------
More Quotes and News: Vivus Inc (Nasdaq:VVUS - news)
Related News Categories: biotech, medical/pharmaceutical
|
